Checchi Capital Advisers LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Checchi Capital Advisers LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,054 shares of the company’s stock after acquiring an additional 1,509 shares during the period. Checchi Capital Advisers LLC’s holdings in Johnson & Johnson were worth $5,802,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Atlantic Private Wealth LLC bought a new stake in Johnson & Johnson during the first quarter valued at approximately $32,000. 25 LLC bought a new stake in Johnson & Johnson during the first quarter valued at approximately $55,000. Horizons Wealth Management lifted its position in Johnson & Johnson by 1,730.0% during the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after purchasing an additional 346 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $66,000. Finally, Mcmillion Capital Management Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $103,000. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $149.91 on Tuesday. The stock has a market cap of $360.88 billion, a price-to-earnings ratio of 11.13, a PEG ratio of 3.00 and a beta of 0.58. The firm’s 50-day moving average is $154.52 and its 200 day moving average is $160.29. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.14. The company had revenue of $21.35 billion for the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. Sell-side analysts anticipate that Johnson & Johnson will post 10.1 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Monday, November 20th. Johnson & Johnson’s dividend payout ratio is currently 35.34%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Friday. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a report on Thursday, August 31st. Atlantic Securities upped their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday. Finally, Barclays upped their price target on shares of Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a report on Thursday, October 12th. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $169.19.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.